Thursday Apr 17
Last leader of violent animal rights group jailed for six years
Debbie Vincent was part of group that falsely accused Huntingdon Life Sciences workers of being paedophiles, posted sanitary towels claimed to be infected with AIDS, and desecrated the grave of the mother of a pharmaceutical company director Note: We do not store your email address but your IP address will be logged to prevent abuse of this ... (more)
Trending on the Topix Network
Tue Apr 15, 2014
Novartis AG Ditches RNAi Development In Boston, Job Cuts Cited
Novartis isn't the only one hiring, others are hiring too! Check it out! Novartis is shuttering a large part of its once-ambitious RNAi research efforts in Boston, FierceBiotech has learned.
Cambridge Evening News
Stop Huntingdon Animal Cruelty (Shac) campaign against Huntingdon...
An animal rights protest group which aims to close down research firm Huntingdon Life Sciences was dubbed "quasi-terrorist" by an international pharmaceutical company seeking to protect staff against harassment.
Mon Apr 14, 2014
Nucleic Acids Research
Computational modeling identifies key gene regulatory interactions...
Here, we have identified key candidate regulators of phenobarbital -mediated mouse liver tumorigenesis, a well-characterized model of non-genotoxic carcinogenesis, by applying a new computational modeling approach to a comprehensive collection of in vivo gene expression studies.
Sun Apr 13, 2014
China Biotech In Review: WuXi Receives Award For cGMP...
BVCF, a China private equity growth investor specializing in healthcare and life sciences, has closed its third fund, BVCF III, L.P, with capital of $188 million .
Thu Apr 10, 2014
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler Retires
Novartis announced earlier this week the appointment of Jeff George as division head of Alcon , effective May 1, 2014.
Wed Apr 09, 2014
Novartis names new division head at Alcon Labs in Fort Worth
Jeff George, who now heads the Novartis generic drugs division, Sandoz, which has its global headquarters in Holzkirchen, Germany, will succeed Kevin Buehler, who is retiring from Alcon, a eye pharmaceutical maker, after 30 years.
Novartis And MNM Provide 2 Million Anti-Malarial Drugs In Zambia
Novartis announced that two million units of its pediatric anti-malarial drug have been shipped to Zambia as part of ongoing efforts to eradicate the disease under its collaboration with Malaria No More and its campaign Power of One.
Seattle's Juno Therapeutics Pauses Trial After Patient Deaths
One of the most exciting new avenues in cancer research is the development of techniques to genetically re-engineer a patient's own immune cells to destroy tumors.
Tue Apr 08, 2014
FDA Grants Breakthrough Status Designation To Novartis AG' Meningitis B Vaccine
Novartis NVS +0.01% AG in Basel announced early this morning that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation - a rapid development track - for potential approval of BexseroA , their innovative vaccine against type B meningococcal meningitis.
Sun Apr 06, 2014
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
BASEL, SWITZERLAND , Apr. 07 /CSRwire/ - Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign.
Thu Apr 03, 2014
Novartis sues Biocon over patent
Accusing India drug maker Biocon of infringing on its diabetes drug Galvus patent, Novartis goes to Delhi's High Court in an attempt to stop the firm from launching a generic vildagliptin.
Wed Apr 02, 2014
Novartis Price Target Increased to $93.00 by Analysts at Leerink Swann
The firm currently has an "outperform" rating on the stock. Leerink Swann's price target suggests a potential upside of 10.05% from the company's current price.
Tue Apr 01, 2014
Novartis' Lead Ceritinib Could Capture Market Share From Pfizer
Novartis A.G. and worldwide collaborators published results of their Phase I clinical trial of the ALK inhibitor Ceritinib in the New England Journal of Medicine on March 27. Ceritinib is 20X more potent than Crizotinib, more selective, has a similar side-effect profile and offers a second chance when Crizotinib resistance develops.
Mon Mar 31, 2014
Novartis Sets New 1-Year High at $85.23
Novartis shares reached a new 52-week high during trading on Monday , AnalystRatings.NET reports.
Why Novartis (NVS) Stock Is Higher Today
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Investor's Business Daily
Stock Futures Look Favorable; Legg Mason, Novartis, Climb
Stock futures pointed firmly toward a positive open Monday, as the market prepared for the last trading day of March and the final session of the first quarter.
Thu Mar 27, 2014
FDA And Meningitis B: Picking Winners And Losers
The recent death of a Drexel University student due to a rare meningitis B strain is an unquestionable tragedy; one that is made all the more tragic because two vaccines for this strain already exist .
Novartis lung-cancer drug produces response in over half of patients
Novartis' Ceritinib reduced the size of tumors in 58% of patients in a Phase I study of those suffering from a form of lung cancer that strikes 10,000 people a year in the U.S. Ceritinib is the leader of a class of drugs that targets a gene known as ALK and is 20 times as effective as a drug from Pfizer called Xalkori.
Tue Mar 25, 2014
VEA, RUSL: Big ETF Inflows
Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF , which added 8,499,999 units, or a 1.7% increase week over week.